Cassava Sciences (SAVA) News Today $1.38 -0.05 (-3.15%) As of 12:02 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Short Interest in Cassava Sciences, Inc. (NASDAQ:SAVA) Declines By 17.8%Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 11,880,000 shares, a decrease of 17.8% from the February 28th total of 14,450,000 shares. Based on an average trading volume of 2,270,000 shares, the short-interest ratio is presently 5.2 days. Currently, 27.1% of the shares of the stock are sold short.April 3, 2025 | marketbeat.comNotable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focusMarch 30, 2025 | msn.comCassava Sciences must face malicious prosecution lawsuit over Alzheimer's drugMarch 26, 2025 | reuters.comHC Wainwright Reiterates Neutral Rating for Cassava Sciences (NASDAQ:SAVA)HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 price objective on shares of Cassava Sciences in a research note on Tuesday.March 26, 2025 | marketbeat.comCassava ends simufilam Alzheimer’s programme after second Phase III failureMarch 26, 2025 | finance.yahoo.comCassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpointMarch 26, 2025 | markets.businessinsider.comCassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’sMarch 26, 2025 | markets.businessinsider.comCassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains HopefulMarch 26, 2025 | msn.comCassava to phase out Alzheimer’s program by Q2March 25, 2025 | msn.comCassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be DiscontinuedMarch 25, 2025 | marketwatch.comCassava to discontinue development of Alzheimer's disease drugMarch 25, 2025 | msn.comCassava Sciences' controversial Alzheimer's drug fails in second late-stage studyMarch 25, 2025 | msn.comCassava Sciences Reports Topline Phase 3 REFOCUS-ALZ DataMarch 25, 2025 | globenewswire.comCassava Sciences: Downside From Alzheimer's Results Still Possible Despite New DevelopmentsMarch 21, 2025 | seekingalpha.comCassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comHC Wainwright Lifts Earnings Estimates for Cassava SciencesCassava Sciences, Inc. (NASDAQ:SAVA - Free Report) - Equities research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Cassava Sciences in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now anticipates that theMarch 8, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Given Neutral Rating at HC WainwrightHC Wainwright restated a "neutral" rating on shares of Cassava Sciences in a research note on Tuesday.March 5, 2025 | marketbeat.comCassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term ValueMarch 4, 2025 | seekingalpha.comH.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might revealMarch 4, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)March 4, 2025 | markets.businessinsider.comCassava Sciences, Inc.: Cassava Sciences Reports 2024 Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deCassava Sciences reports Q4 EPS (57c) vs (50c) last yearMarch 3, 2025 | markets.businessinsider.comCassava Sciences (NASDAQ:SAVA) Posts Quarterly Earnings Results, Beats Estimates By $0.42 EPSCassava Sciences (NASDAQ:SAVA - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.42.March 3, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Announces Quarterly Earnings ResultsCassava Sciences (NASDAQ:SAVA - Get Free Report) issued its earnings results on Monday. The company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.42.March 3, 2025 | marketbeat.comCassava Sciences Reports 2024 Financial Results and Provides Business UpdateMarch 3, 2025 | globenewswire.comH.C. Wainwright Reaffirms Their Hold Rating on Cassava Sciences (SAVA)February 28, 2025 | markets.businessinsider.comCassava Sciences stock jumps on new patent licenseFebruary 27, 2025 | za.investing.comCassava Sciences Licenses Simufilam Method of Treatment PatentFebruary 27, 2025 | markets.businessinsider.comBook review: 'Doctored' investigates twists and turns of Alzheimer's drug scandalFebruary 22, 2025 | yahoo.comCassava Sciences (SAVA) to Release Earnings on WednesdayCassava Sciences (NASDAQ:SAVA) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comSAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud LawsuitFebruary 10, 2025 | prnewswire.comCassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVAFebruary 10, 2025 | globenewswire.comCassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ...February 10, 2025 | gurufocus.comCassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVAFebruary 10, 2025 | prnewswire.comHow greed and profit fueled one failed Alzheimer drugFebruary 10, 2025 | nypost.comSAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVAFebruary 9, 2025 | globenewswire.comFINAL SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Join the Class Action LawsuitFebruary 9, 2025 | investing.comLead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the FirmFebruary 9, 2025 | prnewswire.comSAVA IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in SecuFebruary 8, 2025 | investing.comSAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. ...February 8, 2025 | gurufocus.comCASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class ...February 8, 2025 | businesswire.comSAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action LawsuitFebruary 8, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVAFebruary 7, 2025 | globenewswire.comSAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their RightsFebruary 7, 2025 | businesswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaFebruary 7, 2025 | prnewswire.comShareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreFebruary 7, 2025 | prnewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) ShareholdersFebruary 6, 2025 | globenewswire.comSAVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVAFebruary 6, 2025 | globenewswire.comCassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVAFebruary 6, 2025 | prnewswire.comClinical trials site shows Cassava Sciences REFOCUS-ALZ trial terminatedFebruary 5, 2025 | markets.businessinsider.com Remove Ads Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Media Mentions By Week SAVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAVA News Sentiment▼0.740.79▲Average Medical News Sentiment SAVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAVA Articles This Week▼18▲SAVA Articles Average Week Remove Ads Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atea Pharmaceuticals News Today Aquestive Therapeutics News Today Candel Therapeutics News Today Astria Therapeutics News Today Alumis News Today MBX Biosciences News Today Aurora Cannabis News Today Bright Minds Biosciences News Today Compass Therapeutics News Today Lifecore Biomedical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAVA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAVA Stock Free SAVA Stock Alerts